Ribavirin: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients, but since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C by inhibiting the synthesis of viral RNA. <ref>https://pubchem.ncbi.nlm.nih.gov/compound/37542<ref> The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b. <ref name="gish"/> | Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients, but since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C by inhibiting the synthesis of viral RNA. <ref>https://pubchem.ncbi.nlm.nih.gov/compound/37542<ref> The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b. <ref name="gish"/> | ||
== Protein Interaction== | == Protein Interaction == | ||
=== Ribavirin with 3SFU=== | === Ribavirin with 3SFU=== | ||
Ribavirin interacts with 3SFU by attaching the binding pocket, which is comprised of tyrosine at position 344 and aspartic acid at positions 250, 346, and 347. | Ribavirin interacts with 3SFU by attaching the binding pocket, which is comprised of tyrosine at position 344 and aspartic acid at positions 250, 346, and 347. | ||
